...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >mRNA Expression of Bax, Bcl-2, p53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 Cell Line Following Induction by a Novel Monoclonal Ab Hep88 mAb: Cross-Talk for Paraptosis and Apoptosis
【24h】

mRNA Expression of Bax, Bcl-2, p53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 Cell Line Following Induction by a Novel Monoclonal Ab Hep88 mAb: Cross-Talk for Paraptosis and Apoptosis

机译:通过新型单克隆ABHEP88 MAB诱导后HepG2细胞系中Bax,Bcl-2,P53,组织蛋白酶B,Caspase-3和Caspase-9的mRNA表达:串扰为患有肺组织和凋亡

获取原文
           

摘要

Monoclonal antibodies with specific antigens have been widely used as targeted therapy for cancer. Hep88 mAb is a monoclonal antibody which shows specific binding with anti-cancer effects against the HepG2 cell line. However, its mechanisms of action are still not completely understood. We examined cell cycling and apoptosis by flow cytometry and mRNA expression of factors involved in apoptosis and paraptosis in Hep88 mAb-treated HepG2 cells by real-time PCR. The cell-cycle analysis demonstrated that growth-inhibitory activity was associated with G2/M cell cycle arrest. Hep88 mAb induced a significant increase in apoptotic cell populations in a dose- and time-dependent manner. The mRNA expression results also suggested that the process triggered by Hep88 mAb involved up-regulation of tumor suppressor p53, pro-apoptotic Bax, Cathepsin B, Caspase-3 and Caspase-9, with a decrease of anti-apoptotic Bcl-2 - thus confirming paraptosis and apoptosis programmed cell death. These findings represent new insights into the molecular mechanisms underlying the anti-cancer properties of Hep88 mAb in liver cancer cells.
机译:具有特异性抗原的单克隆抗体已被广泛用作癌症的靶向治疗。 Hep88 mAb是一种单克隆抗体,其显示与抗癌作用对HepG2细胞系的特异性结合。但是,它的行动机制仍然没有完全理解。通过实时PCR,通过流式细胞术和流式细胞术和细胞凋亡和mRNA表达进行细胞循环和细胞凋亡,通过实时PCR通过实时PCR进行HEP88 MAB处理的HEPG2细胞的影响。细胞循环分析表明生长抑制活性与G2 / M细胞循环骤停有关。 Hep88 mAb以剂量和时间依赖的方式诱导凋亡细胞群的显着增加。 MRNA表达结果还表明HEP88 MAB触发的过程涉及肿瘤抑制P53,促凋亡坝,组织蛋白酶B,Caspase-3和Caspase-9的上调,降低抗凋亡Bcl-2 - 因此确认浸渍性和细胞凋亡计划的细胞死亡。这些发现代表了对肝癌细胞Hep88 mAb抗癌性质的分子机制的新见解。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号